ASCO 2022 | KEYNOTE-012: retrospective analysis exploring potential biomarkers for IO in advanced solid tumors

Ranee Mehra, MD, University of Maryland Marlene & Stewart Greenebaum Cancer Center, Baltimore, MD, discusses results of a retrospective analysis based on tissue that was collected during the Phase I KEYNOTE-012 (NCT01848834) trial attempting to evaluate potential biomarkers for immunotherapy. Tumor mutation and gene expression profiling was found to be associated with a higher chance of response to pembrolizumab. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.